Citigroup Downgrades Boston Scientific to Neutral, Lowers Price Target to $50
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsDowngradesPrice TargetHot
Citigroup analyst Joanne Wuensch downgrades Boston Scientific (NYSE:BSX) from Buy to Neutral and lowers the price target from $57 to $50.
Citigroup analyst Joanne Wuensch downgrades Boston Scientific (NYSE:BSX) from Buy to Neutral and lowers the price target from $57 to $50.